2164-67-2 Usage
Uses
Used in Pharmaceutical Industry:
2-Amino-6-hydroxymethylpyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-6-hydroxymethylpyrimidine is utilized as a building block in the creation of agrochemicals, potentially enhancing crop protection and yield through the development of novel compounds.
Used in Chemical Research:
2-Amino-6-hydroxymethylpyrimidine serves as a valuable compound in chemical research, where it is studied for its potential biological activities, including its role as a protein kinase inhibitor, which could lead to advancements in the treatment of various diseases.
Used in Anti-inflammatory and Antiviral Applications:
Due to its anti-inflammatory and antiviral properties, 2-Amino-6-hydroxymethylpyrimidine is explored for use in medicinal applications, potentially offering new avenues for the treatment of inflammation and viral infections.
Check Digit Verification of cas no
The CAS Registry Mumber 2164-67-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,6 and 4 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2164-67:
(6*2)+(5*1)+(4*6)+(3*4)+(2*6)+(1*7)=72
72 % 10 = 2
So 2164-67-2 is a valid CAS Registry Number.
2164-67-2Relevant academic research and scientific papers
INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION
-
, (2012/10/08)
The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.
